Natco Pharma, one of the few Indian companies to venture into new drug discovery research, witnessed a rise in share price on Thursday after it announced that it is the first company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India).

Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi®.

Shares of the company are trading at Rs 1,882.90, up Rs 90.85, or 5.07% at the Bombay Stock Exchange (BSE) on Thursday at 11:04 a.m.

The scrip has touched an intra-day high of Rs 1,885 and low of Rs 1,795.20. The total volume of shares traded at the BSE is 34,998.